This activity is no longer available for credit, however its content is still (may still be) relevant for your educational needs.

Valid: March 31st, 2009 - March 31st, 2010

This activity is no longer available for credit, however its content is still relevant for your educational needs.

Statement of Need
The purpose of this activity is to enhance knowledge concerning the treatment of patients with relapsed and refractory multiple myeloma (MM).

Target Audience
This activity was developed for physicians, nurses, and pharmacists.

Learning Objectives
At the completion of this activity participants should be able to:

• Describe how standard therapy may be improved with novel agents and treatment approaches for patients with relapsed and refractory multiple myeloma (MM)
• Summarize new data from clinical trials in relapsed/refractory MM as reported at the 2008 American Society of Hematology annual meeting
• Review the side effect profiles of novel agents for MM
• Identify effective strategies for the management of common toxicities associated with MM therapies

Disclosure Statement
Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with the manufacturer(s) of any commercial products(s) to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers’ bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:



Faculty Disclosures
*Sagar Lonial, MD, is a consultant for Bristol-Myers Squibb, Celgene, Millennium, and Novartis, and has received research support from Bristol-Myers Squibb, Celgene, Gloucester, Millennium, and Novartis.

*Jeffrey Wolf, MD, is on the speaker’s bureau for Celgene, Centocor, Ortho Biotech, and Millennium.

Charise Gleason, MSN, ANP-BC, AOCNP, is a consultant for Merck and Millennium.

R. Donald Harvey, PharmD, FCCP, BCPS, BCOP has nothing to disclose.


*Content will include non-FDA-approved uses.

Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition.